Product Code: BIO211A
Highlights:
The global market for cell therapy biomanufacturing should grow from $6.5 billion in 2020 to $10.2 billion by 2025, at compound annual growth rate (CAGR) of 9.4% for the period of 2020-2025.
The type of therapy for cell therapy biomanufacturing should grow from $3.6 billion in 2020 to $5.4 billion by 2025, at a CAGR of 8.4% for the period of 2020-2025.
The source of cells for cell therapy biomanufacturing should grow from $2.9 billion in 2020 to $4.8 billion by 2025, at a CAGR of 10.6% for the period of 2020-2025.
Report Scope:
This research report presents an in-depth analysis of the global cell therapy biomanufacturing market by product type, application and region. The report discusses the key inhibitors to the growth of cell therapy biomanufacturing. The report discusses the role of participants in the supply chain from manufacturers to researchers. The report analyzes key companies operating in the global cell therapy biomanufacturing market. In-depth patent analysis in the report will provide a look at the existing and coming technological trends.
In this report, the cell therapy biomanufacturing market is segmented by product type, application and region. Based on product type, the market is segmented into source of cells (T-cells, Dendritic cells, tumor cells and stem cells), and type of therapy (autologous cell therapies, allogeneic cell therapies). The market by application is categorized into cardiovascular diseases, bone repair, neurological disorders, skeletal muscle repair, cancer and others. The market by region is segmented into North America, Europe, Asia-Pacific and ROW.
Report Includes:
- 23 tables
- An overview of the global markets for cell therapy biomanufacturing
- Estimation of the market size and analyses of global market trends with data from 2019, 2020, and projections of compound annual growth rates (CAGRs) through 2025
- Assessment of market dynamics such as drivers, restraints, opportunities, and identification of growth inhibiting areas that affect the global market
- Detailed description of allogeneic (third party donor cells) and autologous (one's own body cells) forms of cell therapy and analysis of its advantages and limitations
- Information on clinical trials of cell therapies; insights into regulatory scenarios and initiatives by government organization
- Evaluation of current market trends, market size, market forecast, and technological advancements within the industry
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies; and a relevant patent analysis
- Company profiles of major players of the industry, including Bristol-Myers Squibb Co., Caladrius Biosciences Inc., Lonza Group Ltd., Merck KGaA and Novartis AG
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Methodology
- Market Estimates
- Information Sources
- Primary Research
- Secondary Research
- Geographic Breakdown
- Analyst's Credentials
- BCC Custom Research
- Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
- Introduction to Cell Therapy Biomanufacturing
- What is Cell Therapy?
- Stem Cell Transplantation
- Autologous
- Allogeneic
- Syngeneic
- Stem Cell Biomanufacturing and Classification
- Based on Ability to Differentiate
- Based on Source
- Classification of Cell-Based Therapy Technology
- Somatic Cell Technologies
- Three-Dimensional Technologies
- Cell Immortalization Technologies
- Genome Editing Technologies
- Cell Plasticity Technologies
- Ex vivo Gene Modification of Cells Using Viral Vector Technologies
- In vivo Gene Modification of Cells Using Viral Vector Technologies
- Stem Cell Applications
- Mechanism of Cell Therapy
- Delivery Method of Cell-Based Therapy
- Manufacturing Cell Therapy Models
- Role of Contract Manufacturers
- Ongoing Clinical Trials
- Clinical Trial Network Focused on Stem Cell Treatments
Chapter 4 Market Trends and Challenges
- Challenges
- Drivers
- Restraints
- Opportunity
Chapter 5 Market Breakdown by Product Type
- Type of Therapy
- Source of Cells
- Rise in the Demand for Chimeric Antigen Receptor (CAR) T Cell Therapy
Chapter 6 Market Breakdown by Application
- Cardiovascular Disease
- Microparticles Cell Imitation
- Bone Repair
- Neurological Disorders
- Spinal Cord Injury
- Stroke
- Parkinson's Disease
- Amyotrophic Lateral Sclerosis
- Multiple Sclerosis
- Cerebral Palsy
- Alzheimer's Disease
- Vision Restoration
- Vertebral Repair
- Batten's Disease
- Skeletal Muscle Repair
- Intrinsic Healing Mechanisms
- Cell Therapy Mechanism
- Cancer
- Other Diseases
Chapter 7 Market Breakdown by Region
- Market Overview
- North America
- U.S.
- Canada
- Mexico
- Europe
- Cardiovascular Diseases in Europe
- Contributing Factors for Cardiovascular Diseases (CVD)
- Germany
- U.K.
- France
- Asia-Pacific
- China
- India
- Japan
- Rest of APAC
- Rest of the World
- South America
- Middle East and Africa
Chapter 8 Regulatory Structure
- FDA Approvals
- Cell Therapy for CBER Regulations
- Federal Regulation codes
- Collection of Cells
- Code of Regulation
- Legislation Governing Use of Stem Cell Treatments
- EU Determination of Regulatory Status
- Regulatory Scenario in India
Chapter 9 Company Profiles
- BONE THERAPEUTICS SA
- BRISTOL-MYERS SQUIBB CO.
- CALADRIUS BIOSCIENCES INC.
- CELL THERAPIES PTY LTD.
- CELLULAR BIOMEDICINE GROUP INC.
- IOVANCE BIOTHERAPEUTICS INC.
- LONZA GROUP LTD.
- MERCK KGAA
- NEUROGENERATION INC.
- NOVARTIS AG
- REGEN BIOPHARMA INC.
- REGENEUS LTD.
Chapter 10 Appendix: References
比較リスト
